CureVac GmbH

News

CureVac GmbH; CureVac Receives IND Approval From The FDA To Start Its Phase I/IIa mRNA Vaccine Clinical Trial In Prostate Cancer

🕔1/5/2009 10:51:00 PM 917

* CureVac's RNActive® mRNA vaccine CV9103 to treat prostate cancer is approved for clinical studies in the US * First US clinical trial expected to begin in March 2009 * First results expected in H1 2010

Lesen Sie die komplette Artikel▸

CureVac GmbH; CureVac To Start First Mrna Vaccine Clinical Trial In Prostate Cancer

🕔12/10/2008 9:03:00 PM 991

* CureVac's RNActive® mRNA vaccine CV9103 to treat prostate cancer approved for study in humans * Clinical trial to begin by year-end * First results expected in Q3 2009